|
|
Volumn 213, Issue 13, 2016, Pages 2831-2833
|
|
Therapy-activated stromal cells can dictate tumor fate
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALDEHYDE DEHYDROGENASE;
ANGIOGENESIS INHIBITOR;
CD24 ANTIGEN;
CHEMOKINE RECEPTOR;
CHEMOKINE RECEPTOR CXCR2;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
HERMES ANTIGEN;
IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;
PACLITAXEL;
STAT1 PROTEIN;
TUMOR PROTEIN;
ADJUVANT CHEMOTHERAPY;
ANTIANGIOGENIC ACTIVITY;
BREAST CANCER;
CANCER CHEMOTHERAPY;
CANCER STEM CELL;
CARCINOMA ASSOCIATED FIBROBLAST;
CARCINOMA CELL;
COCULTURE;
HUMAN;
LUNG METASTASIS;
LYMPH NODE METASTASIS;
MAINTENANCE THERAPY;
MAXIMUM TOLERATED DOSE;
METRONOMIC CHEMOTHERAPY;
NONHUMAN;
NOTE;
PANCREAS CANCER;
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
SIGNAL TRANSDUCTION;
STROMA CELL;
TREATMENT OUTCOME;
TUMOR CELL;
TUMOR GROWTH;
TUMOR INITIATING CELL;
TUMOR INVASION;
TUMOR MICROENVIRONMENT;
ANIMAL;
METABOLISM;
METASTASIS;
METRONOMIC DRUG ADMINISTRATION;
NEOPLASMS;
PATHOLOGY;
ADMINISTRATION, METRONOMIC;
ANIMALS;
HUMANS;
NEOPLASM INVASIVENESS;
NEOPLASM METASTASIS;
NEOPLASM PROTEINS;
NEOPLASMS;
RECEPTORS, CHEMOKINE;
STROMAL CELLS;
|
|
EID: 85008462922
PISSN: 00221007
EISSN: 15409538
Source Type: Journal
DOI: 10.1084/jem.20161845 Document Type: Note |
|
Times cited : (9)
|
|
References (15)
|
